Daiichi Sankyo Company, Limited (DSNKY) Stock Price & Analysis
Daiichi Sankyo Company, Limited (DSNKY) — price $17.39 (+0.35%), as of the Oct 6, 2026 trading session; market cap $31.6B.
Educational signal · not a buy or sell recommendation · How to read this
Daiichi Sankyo Company, Limited · DSNKY · Healthcare · Drug Manufacturers - General
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal…
Price as of Oct 6, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $17.39 |
| Change on the day | +0.35% |
| 52-week range | $14.98–$27.50 |
| Market capitalisation | $31.6B |
| Price / earnings (trailing) | 20.61 |
| Shares traded on the day | 5.9K |
| Beta (volatility vs the S&P 500) | 0.14 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Daiichi Sankyo Company (DSNKY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the DSNKY film — every key number, told as a short cinematic story
~2 min · open the film
What is Daiichi Sankyo Company (DSNKY), and what does it report?
Short answer · as of
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal… Healthcare / Drug Manufacturers General Headquarters: Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP. It employs 20,171 people and is led by Hiroyuki Okuzawa. In Q1 FY2027 it reported revenue of $3.68B and net income of $440M. The market values it at $31.6B.
What do the latest results show for Daiichi Sankyo Company (DSNKY)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $3.68B. Against analyst estimates the company has EPS beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $3.68B | $440M | $0.24 (diluted) |
| Q4 FY2026 | $3.80B | $273M | $0.15 (diluted) |
| Q3 FY2026 | $3.59B | $557M | $0.30 (diluted) |
| Q2 FY2026 | $3.22B | $291M | $0.16 (diluted) |
What are the financial strengths and risks for Daiichi Sankyo Company (DSNKY)?
Short answer
The distress and quality screens read Altman Z 2.92 · Piotroski F 6. Trailing ratios: ROE 14.4% · ROA 5.9% · current ratio 2.92 · earnings yield 4.8% · free-cash-flow yield -0.0%.
How is Daiichi Sankyo Company scored?
Research dated 2026-09-12.
Daiichi Sankyo differs from oncology-focused biotechnology companies because its economics include a broad marketed portfolio, vaccines, consumer health products and pharmaceutical manufacturing activities. Enhertu gives oncology strategic importance, but the company is not a product-pure cancer developer.
Relative to diversified drug manufacturers, its notable feature is the combination of an antibody-drug conjugate franchise with development of a Guardant companion diagnostic for Enhertu in advanced metastatic lung cancer. That pairing links medicine commercialization with patient selection, while the consolidated accounts still blend newer oncology assets with mature therapies and consumer products.
The shares trade through an over-the-counter quotation, while the operating company is headquartered in Tokyo and distributes medicines globally. That listing route differs from the business itself and should not be read as evidence of a narrowly domestic operation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $39.89 Oct 6, 2026 | $52.6B | — Model unavailable | |
| $236.94 Oct 6, 2026 | $44.8B | — Model unavailable | |
| $155.97 Oct 6, 2026 | $52.2B | — Model unavailable | |
| $33.85 Oct 6, 2026 | $56.9B | — Model unavailable | |
| $26.48 Oct 5, 2026 | $79.0B | — Model unavailable | |
| $222.89 Oct 6, 2026 | $33.0B | — 5-pillar · not comparable | |
| $46.60 Oct 6, 2026 | $93.3B | — 5-pillar · not comparable | |
| $39.56 Oct 6, 2026 | $94.9B | — 5-pillar · not comparable | |
| $59.59 Oct 6, 2026 | $120B | — 5-pillar · not comparable | |
| $27.48 Oct 6, 2026 | $156B | — 5-pillar · not comparable | |
| $7.52 Oct 6, 2026 | $6.35B | — 5-pillar · not comparable | |
| $144.23 Oct 6, 2026 | $178B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about Daiichi Sankyo Company (DSNKY)?
- AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
- Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study
- New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
- Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
Daiichi Sankyo Company Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Does Enhertu make Daiichi Sankyo a pure oncology company?
Enhertu is an important antibody-drug conjugate, but Daiichi Sankyo also sells medicines across cardiovascular, metabolic, neurological, pain, bone and infectious diseases, as well as vaccines and consumer health products.
How does the Guardant companion diagnostic fit with Enhertu?
Daiichi Sankyo is collaborating with Guardant Health on a companion diagnostic specifically for Enhertu use in advanced metastatic lung cancer. The development connects treatment commercialization with identification of suitable patients.
What is the DSNKY stock price today?
The last price recorded on this page for Daiichi Sankyo Company, Limited (DSNKY) is $17.39, as of the Oct 6, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 16 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $17.39 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T20:05:02.796Z. | |
px.change | Change on the day | +0.35% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $31.6B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-06. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal… | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.06 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $14.98–$27.50 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 20.61 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5.9K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.14 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers General | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 20,171 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Hiroyuki Okuzawa | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q1 FY2027 | $3.68B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2027 | $440M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.92 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 14.4% · ROA 5.9% · current ratio 2.92 · earnings yield 4.8% · free-cash-flow yield -0.0% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Its extensive and diverse portfolio features numerous key pharmaceutical offerings: Oncology: This includes trastuzumab deruxtecan (an anti-HER2 antibody-drug conjugate for cancer treatment), gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen, an anti-breast cancer agent. Cardiovascular and Metabolic Health: The company provides teneligliptin and a combination of teneligliptin/canagliflozin for managing type 2 diabetes mellitus, along with colesevelam for both hypercholesterolemia and type 2 diabetes. Other notable products in this area are prasugrel, an antiplatelet agent; edoxaban, an anticoagulant; olmesartan, an antihypertensive; and pravastatin for hypercholesterolemia. Neurology and Pain Management: Offerings include mirogabalin for pain relief, lacosamide as an anti-epileptic agent, memantine for Alzheimer's disease, and loxoprofen, an anti-inflammatory analgesic. Bone Health: Denosumab is available for conditions like osteoporosis and other bone disorders. Gastrointestinal and Other Specialized Treatments: This category features esomeprazole for ulcer treatment, silodosin for dysuria, and ferric carboxymaltose and iron sucrose injections to address anemia. Infectious Diseases and Immunology: Daiichi Sankyo markets laninamivir for anti-influenza treatment, levofloxacin as an antibacterial agent, and a range of vaccines including adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. Beyond prescription medications, the company also supplies a variety of consumer healthcare products: Over-the-Counter Remedies: Lulu, a combination cold remedy, and Loxonin S, an antipyretic/anti-inflammatory analgesic. Dermatology and Personal Care: Transino, aimed at improving melasma and treating spots/freckles; Minon skincare products; and oral care solutions like Breath Labo and Clean Dental. Furthermore, Daiichi Sankyo's operations extend to pharmaceuticals and drugs for animals, cosmetics, medical equipment, various food products, drinking water, and active pharmaceutical ingredients (APIs) and intermediates. The company is also engaged in strategic collaborations, notably with Guardant Health to develop Guardant360 CDx, a companion diagnostic specifically for Enhertu in patients with advanced metastatic non-small cell lung cancer. Established in 1899, Daiichi Sankyo Company, Limited maintains its corporate headquarters in Tokyo, Japan. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Ticker / exchange | DSNKY on Other OTC | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Headquarters | Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.